These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8007745

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin.
    O'Day DM, Ray WA, Robinson RD, Head WS.
    Invest Ophthalmol Vis Sci; 1987 Mar; 28(3):596-603. PubMed ID: 3549613
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of cilofungin on phagocytosis and intracellular killing of Candida albicans by human neutrophils.
    Richardson MD, Scott G, Shankland GS.
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):22-6. PubMed ID: 1563379
    [Abstract] [Full Text] [Related]

  • 27. [Phagocytic and intracellular killing activity of rat macrophages: critical analysis of 2 different evaluation methods].
    Iannello D, Bonina L, Carbone M.
    G Batteriol Virol Immunol; 1984 Jan; 77(1-6):45-53. PubMed ID: 6399274
    [Abstract] [Full Text] [Related]

  • 28. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
    Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP.
    J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans.
    Geraghty P, Kavanagh K.
    J Pharm Pharmacol; 2003 Feb; 55(2):179-84. PubMed ID: 12631409
    [Abstract] [Full Text] [Related]

  • 33. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
    Favel A, Michel-Nguyen A, Datry A, Challier S, Leclerc F, Chastin C, Fallague K, Regli P.
    J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Intracellular killing of Candida albicans by human neutrophils is potentiated by exposure to combinations of amphotericin B and 5-fluorocytosine.
    Richardson MD, Paton M, Shankland GS.
    Mycoses; 1991 Mar; 34(5-6):201-4. PubMed ID: 1795714
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.
    Martin E, Stüben A, Görz A, Weller U, Bhakdi S.
    Antimicrob Agents Chemother; 1994 Jan; 38(1):13-22. PubMed ID: 8141565
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.